BIOMAT Database Logo BIOMAT Database Logo

Disposition of 125I-labeled recombinant human tumor necrosis factor in the tumor-bearing mouse. 1988

H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.

Disposition of [125I]rHu-TNF was elucidated in BALB/c mice bearing Meth A fibrosarcoma 7 days after transplantation. After i.v. administration, [125I]rHu-TNF measured by radioactivity and immunoreactivity biphasically decreased in plasma. Tumor level of [125I]rHu-TNF was the maximum at 1 h, then decreased and finally remained essentially constant. After i.t. administration, plasma level reached the maximum at 1 h. Tumor level decreased quickly and then became essentially constant. [125I]rHu-TNF was suggested to be degraded to small fragments in the tumor. Significant distribution of [125I]rHu-TNF was found in the kidney, lung, liver and tumor. Most tissue levels decreased with time in parallel with plasma levels. [125I]rHu-TNF radioactivity was found in proximal convoluted tubules of kidney and in those areas of tumor consisting of degenerating cells with pyknotic nuclei. Urine contained most of administered radioactivity, which being neither immunoreactive nor protein-bound.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007553 Isotope Labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms. Isotope Labeling, Stable,Isotope-Coded Affinity Tagging,Isotopically-Coded Affinity Tagging,Affinity Tagging, Isotope-Coded,Affinity Tagging, Isotopically-Coded,Isotope Coded Affinity Tagging,Labeling, Isotope,Labeling, Stable Isotope,Stable Isotope Labeling,Tagging, Isotope-Coded Affinity,Tagging, Isotopically-Coded Affinity
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Binding and crosslinking of 125I-labeled recombinant human tumor necrosis factor to cell surface receptors.
September 1986, Journal of biochemistry,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
[Effect of 131I-labeled recombinant human tumor necrosis factor-alpha on the nude mice bearing human hepatoma].
September 2009, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Demonstration of membrane receptors for human natural and recombinant 125I-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity.
July 1986, European journal of biochemistry,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors.
September 1985, The Journal of experimental medicine,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.
November 1990, Cancer research,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplantable tumors.
February 1989, The Tohoku journal of experimental medicine,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Pulmonary toxicity of recombinant human tumor necrosis factor.
August 1989, Chest,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Antiviral effects of recombinant human tumor necrosis factor.
January 1987, Lymphokine research,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor.
July 1990, Cancer research,
H Miyazaki, and T Fujii, and H Amejima, and N Mikuriya, and K Nambu, and A Kagemoto, and M Nakao, and Y Oh-e, and K Matsumoto, and Y Matsui
Modulation of lipoprotein lipase activity in mouse peritoneal macrophages by recombinant human tumor necrosis factor.
November 1988, Biochimica et biophysica acta,
Copied contents to your clipboard!